Ovarian cancer: emerging molecular-targeted therapies
Carole SourbierRockville, MD, USAAbstract: With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost...
Guardado en:
Autor principal: | Sourbier C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dd4a34d48c32494997b7bf50af34c666 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer
por: Matthaiou EI, et al.
Publicado: (2014) -
Clinical utility of targeted treatments in the management of epithelial ovarian cancer
por: Twu C, et al.
Publicado: (2012) -
Targeting MET in cancer therapy
por: Hong-Nan Mo, et al.
Publicado: (2017) -
Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy
por: Chen Y, et al.
Publicado: (2015) -
New strategy for monitoring targeted therapy: molecular imaging
por: Teng FF, et al.
Publicado: (2013)